TY - JOUR
T1 - Cytokine profile in patients with multiple sclerosis following vitamin D supplementation
AU - Mahon, B. D.
AU - Gordon, S. A.
AU - Cruz, J.
AU - Cosman, F.
AU - Cantorna, M. T.
PY - 2003/1/1
Y1 - 2003/1/1
N2 - Multiple sclerosis (MS) patients were randomized, in a double blind design, and placed into either a vitamin D supplemented group or a placebo control group. As expected, serum 25-hydroxyvitamin D levels increased significantly following 6 month vitamin D supplementation (17±6 ng/ml at baseline to 28±8 ng/ml at 6 months). Vitamin D supplementation also significantly increased serum transforming growth factor (TGF)-β1 levels from 230±21 pg/ml at baseline to 295±40 pg/ml 6 months later. Placebo treatment had no effect on serum TGF-β1 levels. Tumor necrosis factor (TNF)-α, interferon (IFN)-γ, and interleukin (IL)-13 were not different following vitamin D supplementation. IL-2 mRNA levels decreased following vitamin D supplementation but the differences did not reach significance. Vitamin D supplementation of MS patients for 6 months was associated with increased vitamin D status and serum TGF-β1.
AB - Multiple sclerosis (MS) patients were randomized, in a double blind design, and placed into either a vitamin D supplemented group or a placebo control group. As expected, serum 25-hydroxyvitamin D levels increased significantly following 6 month vitamin D supplementation (17±6 ng/ml at baseline to 28±8 ng/ml at 6 months). Vitamin D supplementation also significantly increased serum transforming growth factor (TGF)-β1 levels from 230±21 pg/ml at baseline to 295±40 pg/ml 6 months later. Placebo treatment had no effect on serum TGF-β1 levels. Tumor necrosis factor (TNF)-α, interferon (IFN)-γ, and interleukin (IL)-13 were not different following vitamin D supplementation. IL-2 mRNA levels decreased following vitamin D supplementation but the differences did not reach significance. Vitamin D supplementation of MS patients for 6 months was associated with increased vitamin D status and serum TGF-β1.
UR - http://www.scopus.com/inward/record.url?scp=0037223587&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0037223587&partnerID=8YFLogxK
U2 - 10.1016/S0165-5728(02)00396-X
DO - 10.1016/S0165-5728(02)00396-X
M3 - Article
C2 - 12507780
AN - SCOPUS:0037223587
VL - 134
SP - 128
EP - 132
JO - Advances in Neuroimmunology
JF - Advances in Neuroimmunology
SN - 0165-5728
IS - 1-2
ER -